What's New at CBER

You are subscribed to  What's New at CBER for the U.S. Food & Drug Administration (FDA)

What's New Today

The following links have been updated recently:

Posted: 10/16/2023

• CBER Cures Vacancy Announcement - Lead Program Analyst, AD-0343-Band C, Office of Management (OM), Division of Acquisition and Budget Resources (DABR), Acquisition Management Branch (AMB)

We will launch a #crowdsourcing campaign Oct 30th to gather ideas on major advances in product development for CBER-regulated products including novel products and product manufacturing methods to emerge in the next 3-10 years. PREVIEW QUESTIONS AND GET MORE INFO NOW. https://fda-cber.ideascalegov.com 

Workshops, Meetings & Conferences

October Cellular, Tissue, and Gene Therapies Advisory Committee Meeting October 31, 2023

November Electronic Submission of Adverse Event Reports to FDA Adverse Event Reporting System (FAERS) using International Council for Harmonisation (ICH) E2B(R3) Standards November 7, 2023

2024

Workshops, Meetings & Conferences

Public Workshop: Biomarker-driven Drug Development for Allergic Diseases and Asthma; Public Workshop

February 22, 2024

Update

Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program

FDA will begin accepting requests to participate in year two of the CDRP on October 2, 2023

Request for Comments

Draft Guidance on Manufacturing Changes

New draft guidance on manufacturing changes and comparability for human cellular and #GeneTherapy products. Listen to this recorded webinar for a high-level overview and submit comments to the docket by November 13, 2023: